



Response document for MHRA public consultation on the
proposal to make Dovonex Psoriasis Ointment available in Pharmacies
Ref: ARM95

ANNEX 1

Your details

Name: [REDACTED]

Position (if applicable): Professional Support Pharmacist

Organisation (if applicable): Royal Pharmaceutical Society

Email: [REDACTED]

1. Do you consider that Dovonex Psoriasis Ointment should be available as a Pharmacy medicine?

Yes No Not sure

Please provide any comments or evidence to support your response:

The Royal Pharmaceutical Society supports the proposal to make Dovonex Psoriasis Ointment available as a Pharmacy medicine. Pharmacists are experts in medicines and are well trained to ensure safe supply of medicines to the public. Pharmacists are currently able to sell products for the treatment of psoriasis with appropriate advice on management and application.

2. Do you have any specific comments on the leaflet or the label provided in the public reclassification report for Dovonex Psoriasis Ointment?

PIL:

The PIL mentions that Dovonex Psoriasis Ointment should not be used on the face, does this also include the ears and neck?

Section 2 Excess calcium in the blood

Pharmacists are also trained to advise on side effects and may be more accessible than a doctor. We would suggest also including pharmacists so that the statement reads 'tell your doctor or pharmacist straight away.'

Is there a limit on the quantity that can be supplied at any one time?

If the skin becomes cracked or open can Dovonex Psoriasis Ointment still be used?

3. Do you have any other comments on the reclassification?

N/A

4. The MHRA may publish consultation responses. Do you want your response to remain confidential?

Yes Partially* No

*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gsi.gov.uk) to arrive by 20 April 2017. Contributions received after that date cannot be included in the exercise.